Healthcare & Pharma • Quantitative Market Data & AI Analytics
| Metric / Indicator | Current Reading | AI Action Verdict |
|---|---|---|
| RSI (14) Relative Strength | 37.99 | 🔒 Unlock AI Verdict |
| MACD (12, 26, 9) Level / Signal | -1.097 / -0.902 | 🔒 Unlock AI Verdict |
| Bollinger Bands (20, 2) & EMA (50/200) | 56.90 - 61.65 | BULLISH TREND |
| AI News Sentiment & Momentum Score | 82.5 / 100 | High Accumulation |
| AI Hybrid Probability & 30D Target Range | 55.72 - 66.39 | STRONG BUY |
You are viewing raw mathematical RSI (38.0) and MACD (-1.097) computations. To unlock AI interpretation, Bullish/Bearish ratings, Bollinger Bands, Executive Insider Trades, and 30-Day Statistical Trend Charts for Bristol-Myers, download the TradeGPT Android app.
Download on Google Play
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Read more Google Play
